Columbus
Seeking Alpha
NewGenIvf updates on potential reverse merger with COVIRIX
NewGenIvf Group (NASDAQ:NIVF) announced an update on its proposed reverse merger with pharmaceutical company COVIRIX Medical Pty Ltd. The company reports steady progress in its due diligence efforts and, contingent upon meeting all regulatory requirements, anticipates completing the Proposed Transaction by the end of August 2024. Source: Press Release.
Nuvation Bio announces updates for its ROS1 inhibitor, Taletrectinib
Nuvation Bio (NYSE:NUVB) on Tuesday announced multiple updates for its taletrectinib program. The company said that it would present pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society of Medical Oncology Congress 2024, which will support Nuvation Bio’s New Drug Application in the United States.
Verastem Oncology announces proposed offering of common stock, warrants and pre-funded warrants
Verastem Oncology (NASDAQ:VSTM) intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants. All of the securities to be sold in the offering are to be sold by Verastem Oncology. Source: Press Release.
Laidlaw cuts MEI Pharma to hold over shutdown concerns
Laidlaw downgraded MEI Pharma (NASDAQ:MEIP) to hold over concerns the company may cease operations. The investment group noted MEI’s (MEIP) board has decided to begin evaluating the company’s strategic options, including a possible wind down of its operations. Laidlaw withdrew its price target of $20 to reflect uncertainty...
Brookfield Corporation: Double-Digit Upside Potential Post Rate Cuts
BN currently trades at fair value. But given its exposure to a number of interest rate sensitive segments, it's bound to perform well when rates decline. Brookfield is a well-known asset manager with almost a Trillion dollars in assets under management and consists of a number of entities. At the top of the Brookfield empire sits the holding company - Brookfield Corporation (NYSE:BN).
LL Flooring: The Founder Returns To Clean House
LL Flooring Holdings, Inc., rebranded from Lumber Liquidators in 2020, has been underperforming peers for years and facing bankruptcy rumors. Lumber Liquidators' founder Thomas Sullivan made multiple recent offers to buy the company and was rebuffed, but he just won a proxy battle and joined the Board. Introduction. Opportunities like...
First Horizon Needs To Transition From Stabilization To Growth
First Horizon has been challenged over the past year not only by higher deposit costs and weakening loan demand, but also the need to regrow deposits after Toronto-Dominion walked away. Q2 earnings missed expectations by a marginal amount, but the Street didn't like the weaker net interest income guide, as...
Compass a new outperform at RBC on optimism for psychedelic-based therapies
RBC Capital Markets has initiated Compass Pathways (NASDAQ:CMPS) at outperform with speculative risk as it sees its pipeline of psychedelic-based medicines for mental illnesses as promising. The firm has a $23 price target (~210% upside based on July 22 close). While analyst Leonid Timashev noted that the psychedelic therapy sector...
Centene drops even as Q2 forecasts beat estimates
Shares of Centene (NYSE:CNC) dropped on Tuesday even as the Medicaid-focused health insurer reported better-than-expected preliminary earnings for Q2 2024, ahead of its quarterly financials expected later this week. In a regulatory filing on Tuesday, Centene (CNC) of Saint Louis, Missouri, said it expects to report $2.42 of adjusted earnings...
Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones
Cellectar Biosciences, Inc. announced that the primary endpoint was met in the pivotal phase 2 CLOVER WaM study, using iopofosine for the treatment of patients with relapsed/refractory Waldenstrom's Macroglobulinemia or WM. The NDA submission of ipofosine for relapsed/refractory WM patients is expected in Q4 of 2024. The potential to have...
MoneyLion: Ready To Roar Again
MoneyLion faces CFPB concerns over paycheck advances with a proposal for new interpretive rules. The financial regulator is focused on the high costs of employer-partnered earned wage products, allegedly not properly disclosed. After a massive snapback rally following a reverse split, MoneyLion (NYSE:ML) has again hit turbulence due to regulators....
Jefferies cuts Inmode to hold, cites macro pressures
Jefferies has downgraded Inmode (NASDAQ:INMD) to hold, citing ongoing macroeconomic pressures on the aesthetics market. The investment bank said in a note that Inmode "continues to struggle to bring increased demand to its new platforms, which could impact 2H24." Jefferies added that it sees Inmode unlikely to achieve even the...
Beam Therapeutics gains as H.C. Wainwright starts at Buy
Gene editing company Beam Therapeutics (NASDAQ:BEAM) traded higher on Tuesday after H.C. Wainwright launched its coverage with a Buy recommendation and an $80 per-share price target. Roughly 966.8K Beam (BEAM) shares have changed hands, compared to the 65-day average of ~1.4M, as the stock hit its highest level in over...
StoneCo: Cheap Valuation Is Not Why I Am Bullish
As a long-term-oriented investor with an extensive investment time horizon, I am attracted to companies with room to grow. A cheap valuation could sweeten the deal. I have been bullish on StoneCo for quite some time and I have remained invested through ups and downs. When I invest in a...
Indivior draws bullish view at Piper Sandler after the selloff
After losing over a third of its value over the past 30 days, Indivior (NASDAQ:INDV) won a bullish rating on Wall Street as Piper Sandler launched its coverage with an overweight recommendation and a $22 per share target. Shares of Indivior (INDV) sold off in early July after the U.K.-based...
Verizon: The Market Is Missing The Forest For The Trees
Verizon is down by more than 6% after reporting a somewhat mixed quarter. The stock is nearly flat year-to-date, which goes against the meaningful progress being made in certain areas. After reporting a somewhat mixed quarter, Verizon Communications (NYSE:VZ) appears less attractive for investors, with the stock falling by more...
ZimVie launches GenTek Restorative Components in U.S.
ZimVie (NASDAQ:ZIMV) said it has launched its GenTek Genuine Restorative Components portfolio in the U.S. after receiving market clearance from the FDA. The GenTek product portfolio has been on the market in Europe since 2019. The products are designed to work with ZimVie’s dental implant systems.
Seeking Alpha
151K+
Posts
1M+
Views
Seeking Alpha is an industry leader in mining the wisdom of the crowds for insights on every topic of interest to investors. Our editors curate investing news and analysis from a network of stock analysts, traders, economists, academics, financial advisers and industry experts — all who engage in our community.
It’s essential to note our commitment to transparency:
Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.